This study was carried out within the framework of the Doctoral Program in Sciences for Sustainable Development financed by the National Fund for Scientific and Technological Development and Technological Innovation (FONDECYT) and the World Bank Group. CDQ was funded by FONDECYT 03-2018- FONDECYT/BM-DOCTORATE PROGRAMS IN STRATEGIC AND GENERAL AREAS- ?Doctorate in Sciences for Sustainable Development?. JRT, SMC, HF and RT are funded by Contrato N? 09-2019-FONDECYT-BM-INC.INV. Funding for open access publishing: Universidad Pablo de Olavide/CBUA. The authors wish to thank Cecilia Pajuelo, Carla Montenegro and Rocio Jara Vilca for their contribution in the laboratory procedures.

Snakebite envenoming is a global neglected disease with an incidence of up to 2.7 million new cases every year. Although antivenoms are so-far the most effective treatment to reverse the acute systemic effects induced by snakebite envenoming, they have a limited therapeutic potential, being unable to completely neutralize the local venom effects. Local damage, such as dermonecrosis and myonecrosis, can lead to permanent sequelae with physical, social, and psychological implications. The strong inflammatory process induced by snake venoms is associated with poor tissue regeneration, in particular the lack of or reduced skeletal muscle regeneration. Mesenchymal stromal cells (MSCs)-based therapies have shown both anti-inflammatory and pro-regenerative properties. We postulate that using allogeneic MSCs or their cell-free products can induce skeletal muscle regeneration in snakebite victims...